Pediatric Cancer

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes

The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes

By

For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Exercise linked to reduced mortality in survivors of childhood cancer

Adult survivors of childhood cancer demonstrate significantly higher mortality compared to the general population, out of proportion to the rate of recurrence for their primary cancer.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Vigorous Exercise Improved Life Expectancy for Adult Survivors of Childhood Cancers

Vigorous Exercise Improved Life Expectancy for Adult Survivors of Childhood Cancers

By

Researchers report on a retrospective cohort analysis that evaluated the long-term effects of vigorous exercise for survivors of childhood cancer.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Relative Survival for AYAs Comparable to General Population After 7 Years

Relative Survival for AYAs Comparable to General Population After 7 Years

By

Survivorship plans for adolescent and young adult survivors need to consider the relative long-term survival for AYAs with certain cancers. Those with certain cancers may have excess long-term mortality.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Does Larotrectinib Offer New Hope to Children With TRK Fusion-Positive Solid Tumors?

Does Larotrectinib Offer New Hope to Children With TRK Fusion-Positive Solid Tumors?

By

Because of the drug's promising safety and efficacy, the first child was treated on trial only 9 months after the first adult with a TRK fusion was treated.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

By

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs